| Conclusion | Not only virus but also host playes an important role in the curative effect of anti-virus therapy. It is necessary to view from the angle of host, adjusting the host's immune status to accelerate the clearance of HCV.;Thus, in European Caucasoids with HuLDi00025, we could not demonstrate a strong association between HLA class II, TNF, and TAP gene polymorphisms and response to interferon treatment.;Chronically infected HCV patients with symptomatic mixed cryoglobulinemia display a number of unique characteristics that differentiate them from asymptomatic patients with HuLDi00025.;These results suggest that particular HLA alleles may have an influence on chronic HCV infection as a host genetic factor in the Korean population.;In conclusion, certain class I alleles are associated with outcome in this homogeneous cohort. More significantly, either HLA-A*03, -DRB1*0101, or -*0401 are carried by an overwhelming majority of those subjects who successfully clear HCV.;HLA genotype influences the host capacity to clear HCV viremia.;of the therapy were evaluated 18 months after the end of treatment.;differ in various counties and areas.;These results suggest that particular HLA alleles may have an influence on the serum ALT level of chronic HCV infection as a host genetic factor in the Chinese population.Conclusion1 |
